false
0000811641
0000811641
2025-08-20
2025-08-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
August 20, 2025
| ImmuCell Corporation |
| (Exact name of registrant as specified in its charter) |
| DE |
|
001-12934 |
|
01-0382980 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
| 56 Evergreen Drive Portland, Maine |
|
04103 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code 207-878-2770
| |
| (Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.10 par value per share |
|
ICCC |
|
The NASDAQ Capital Market |
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
On August 20, 2025, ImmuCell Corporation (the “Company”)
entered into an Allonge to and Amendment of Line of Credit (the “Allonge”) between the Company and Maine Community Bank (MCB)
pursuant to which the Company’s $1 million line of credit with MCB was extended through September 11, 2026. Interest on borrowings
against the Line of Credit is variable at the National Prime Rate per annum.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation
under an Off-Balance Sheet Arrangement of a Registrant
The information included in Item 1.01 of this Current Report on Form
8-K is incorporated into this Item 2.03 of this Current Report on Form 8-K by reference.
Item 9.01. Exhibits.
(d) Exhibits.
| 10.1 |
|
Allonge to and Amendment of Line of Credit Loan between the Company and Maine Community Bank dated August 20, 2025. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
IMMUCELL CORPORATION |
| |
|
| Date: August 25, 2025 |
By: |
/s/ Michael F. Brigham |
| |
|
Michael F. Brigham |
| |
|
President and Chief Executive Officer |
| |
|
|
| Date: August 25, 2025 |
By: |
/s/ Timothy C. Fiori |
| |
|
Timothy C. Fiori |
| |
|
Chief Financial Officer |
Exhibit Index
| Exhibit No. |
|
Description |
| 10.1 |
|
Allonge to and Amendment of Line of Credit Loan between the Company and Maine Community Bank dated August 20, 2025. |
| 104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document). |
